Lancet 379(9816):633640 Sequist LV et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
For accessible summaries of trial evidence see the review on PubMed Central and a practical overview at Healthline
We focused on SLC25A40 here because of the availability of an antibody for the murine form and also because of our evidence that it has an important role in both the ETC and cytokine production in macrophages
Bae S, Kim H, Lee N, et al
Besides, it has been shown that L-Cn displays immune suppressive properties in Crohns disease ( in vitro , and factors that affect plasma L-Cn levels were also primarily explored
Zhang Y, Lu M, Yi Y, Xia L, Zhang R, Li C, et al